卵巢癌患者血清及腹水中可溶性白细胞介素－2受体水平测定

The study of sIL-2R level in the sera aud asciticfluids in patients with ovarian cancer

应用双抗体夹心酶联免疫吸附试验（ＥＬＩＳＡ）检测了３１例卵巢癌患者血清及腹木中可溶性白细胞介素－２受体（ｓＩＬ－２Ｒ）水平，并提纯腹水中的ｓＩＬ－２Ｒ，以观察其对正常者淋巴细胞转化的抑制。结果表明，卵巢癌患者血清中ｓＩＬ－２Ｒ水平明显高于正常者（Ｐ＜０．００１），其中粘液性癌患者的ｓＩＬ－２Ｒ水平明显高于浆液性癌患者（Ｐ＜００１），但与肿瘤的临床分期及是否发生转移均无明显相关；此外，在多数腹水标本中检出高浓度的ｓＩＬ－２Ｒ，经亲合层析纯化的腹水中的ｓＩＬ－２Ｒ对正常者淋巴细胞转化有明显抑制作用。

n 31 patients with ovarian cancer, the sIL-2Rlevel of the sera and ascitic fluids weremeasured byELISA, to investigate the inhibitive effect of sIL-2Rpurified from ascitic flulds on normal lymphocytetransformation, stimulated with phytohemagg lutinin(PHA). The results showed that the sera sIL-2R levelsin the patients were much higher than those in tbenormal controls (857 ± 428kU / L vs 235 ± 90kU / L,P< 0.001) The sera sIL-2R levels in mucinous cancerwere significantiy higher than those in serous cancer(988 ± 539kU / L vs 488 ± 233kU/L P < 0.01 ). But noobvious correlation was observed with thehistopathological grading, nor with metastasis. Higherlevels of sIL-2R were aiso observed in the ascitic. Thenormal lymphocyte transformation stimulated withPHA was significantiy inhibited by high s1L-2R puri-fied from the ascitic fiulds.